Workflow
Flashforge Launches AD5X Multi-Color 3D Printer in the U.S., Already Climbing Bestseller Rankings
Globenewswire· 2025-09-30 12:45
—Prime Big Deal Days Coming SoonNEW YORK, Sept. 30, 2025 (GLOBE NEWSWIRE) -- As one of the early pioneers in consumer 3D printing, Flashforge has always had a knack for turning its products into hits. From the Adventurer, the Creator, to the Finder series, these printers have dominated Amazon bestseller lists for years and earned recommendations from leading media outlets worldwide. The high-speed Adventure 5M (AD5M), in particular, held the #1 spot on Amazon U.S. for 13 consecutive months. Now, this streak ...
Nuwellis Announces 92% Survival in Children with Acute Kidney Injury (AKI), Fluid Overload or Congenital Kidney Failure Following Treatment with Aquadex®
Globenewswire· 2025-09-30 12:45
ULTRA-Peds Registry, the largest multi-center dataset of its kind, shows Aquadex therapy was well-tolerated in critically ill children, a population with extremely limited treatment options Results highlight life-threatening gaps in pediatric care and underscore Nuwellis’ commitment to pediatric innovation and integrated cardio-renal care MINNEAPOLIS, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardio-rena ...
PolyPid to Present Its Positive Phase 3 SHIELD II Topline Results at the 2025 American College of Surgeons Clinical Congress
Globenewswire· 2025-09-30 12:45
The Company will present the reported topline results from its phase 3 SHIELD II trial at one of the world’s leading surgical conferencesPETACH TIKVA, Israel, Sept. 30, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that Dr. Shmuel Sharoni will present the topline results from the Company's successful Phase 3 SHIELD II trial of D-PLEX₁₀₀ at the upcoming 2025 American College of Surgeons (A ...
HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor “What This Means” Segment About its Proprietary T-Cell Engager Program
Globenewswire· 2025-09-30 12:45
Watch the "What This Means" video here Featuring Company’s second-generation T-Cell Engager program and advantages over first-generation Company’s T-Cell Engager program has made improvements in manufacturability, preclinical safety profile, and ability to treat a wide spectrum of solid tumors MIRAMAR, Fla., Sept. 30, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing nove ...
24/7 Market News: Sportswear and Smart Textiles are likely Key Spider Silk Target Markets for Kraig Labs
Globenewswire· 2025-09-30 12:45
DENVER, Sept. 30, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and information, highlights the opportunity for recombinant spider silk produced by Kraig Biocraft Laboratories (OTCQB: KBLB), the global leader in the development and commercialization of spider silk. 24/7 Market News believes that some of the most obvious projected use-cases include compression gear, perspiration-wicking layers, temperature-regulating base l ...
ADT Announces $1.0 Billion Notes Offering
Globenewswire· 2025-09-30 12:44
BOCA RATON, Fla., Sept. 30, 2025 (GLOBE NEWSWIRE) -- ADT Inc. (NYSE: ADT) (the “Company” or “ADT”), today announced that its indirect wholly owned subsidiary, The ADT Security Corporation, is proposing to issue and sell $1.0 billion aggregate principal amount of first-priority senior secured notes due 2033 (the “Notes”) in an offering that will be exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”) (the “Offering”). The Company intends to use the procee ...
Silexion Therapeutics Announces Positive New Human Cell Line Data Confirming Pan-KRAS Activity of SIL204, Demonstrating Up to 99.7% Inhibition and First Evidence in Gastric Cancer
Globenewswire· 2025-09-30 12:40
New data in human cancer cell lines provides confirmation of pan-KRAS mutation inhibition with inhibition of G12D, G12V, G12R, G12C, G13C, G12A, Q61H, and G13D mutations Company Reports first evidence of gastric cancer activity expands potential therapeutic reach of SIL204 GRAND CAYMAN, Cayman Islands, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven ...
Transocean Ltd. Announces Proposed Private Offering of Senior Priority Guaranteed Notes Due 2032
Globenewswire· 2025-09-30 12:32
STEINHAUSEN, Switzerland, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Transocean Ltd. (NYSE: RIG) announced today that Transocean International Limited, a Bermuda exempted company limited by shares and a wholly owned subsidiary of Transocean Ltd. (the “Company” and, together with Transocean Ltd., “Transocean”), commenced a private offering of $500 million aggregate principal amount of Senior Priority Guaranteed Notes due 2032 (the “Notes”) to eligible purchasers pursuant to Rule 144A/Regulation S (the “Notes Offerin ...
Barnes & Noble College Launches Campus to Career, a NEW Offering to Help Students Build Real-World Skills to Enter the Workforce
Globenewswire· 2025-09-30 12:31
BASKING RIDGE, N.J., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Barnes & Noble College (BNC), a Barnes & Noble Education, Inc. (NYSE: BNED) company and leading solutions provider for higher education, today announced the launch of Campus to Career — a new offering designed to equip college students with the tools, resources and insights they need to help transition from the classroom to the workplace. Campus to Career offers a curated collection of products available both in-store and online, along with an exclusiv ...
Tiziana Life Sciences Invited to Attend Life Sciences Innovation Forum 2025 in Riyadh, Saudi Arabia
Globenewswire· 2025-09-30 12:30
BOSTON, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that it has been invited to attend the J.P. Morgan Asset Management, Life Science Innovation Forum (LSIF) 2025 in Collaboration with KAIMRC, taking place October 1–2, 2025, at the King Saud bin Abdulaz ...